TXA709, an FtsZ-targeting benzamide prodrug with improved pharmacokinetics and enhanced in vivo efficacy against methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4845-4855

  Kaul, Malvika ^a   Mark, Lilly ^b,c   Zhang, Yongzheng ^b   Parhi, Ajit K ^b,c   Lyu, Yi Lisa ^a   Pawlak, Joan ^d   Saravolatz, Stephanie ^d   Saravolatz, Louis D ^d,e   Weinstein, Melvin P ^f   LaVoie, Edmond J ^c   Pilcha, Daniel S ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b TAXIS Pharmaceuticals Inc   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; ANTIBIOTIC AGENT; BENZAMIDE DERIVATIVE; DAPTOMYCIN; FTSZ PROTEIN; LINEZOLID; PC 190723; PRODRUG; TXA 707; TXA 709; TXY 541; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BENZAMIDE; CYTOSKELETON PROTEIN; FTSZ PROTEIN, BACTERIA; METICILLIN; PC190723; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PERITONITIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG TARGETING; ELIMINATION HALF-LIFE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LINEZOLID RESISTANT STAPHYLOCOCCUS AUREUS; LIVER CELL; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC STABILITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; STAPHYLOCOCCUS AUREUS; TIME TO MAXIMUM PLASMA CONCENTRATION; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; DOG; DRUG EFFECTS; HALF LIFE TIME; METABOLISM; MICROBIAL SENSITIVITY TEST; PENICILLIN RESISTANCE; PROCEDURES; RAT; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BENZAMIDES; CELLS, CULTURED; CYTOSKELETAL PROTEINS; DAPTOMYCIN; DOGS; HALF-LIFE; HUMANS; LINEZOLID; METHICILLIN; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; PRODRUGS; PYRIDINES; RATS; STAPHYLOCOCCAL INFECTIONS; THIAZOLES; VANCOMYCIN;

EID: 84940179342     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00708-15     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention. September 2013. Antibiotic resistance threats in the United States, 2013. CDC, Atlanta, GA. http: //www.cdc.gov/drugresistance/threat-report-2013/.
2. st century. Perspect Medicin Chem 6:25-64.
3. Moellering RC, Jr. 2012. MRSA: the first half century. J Antimicrob Chemother 67:4-11. http://dx.doi.org/10.1093/jac/dkr437.
4. Otto M. 2012. MRSA virulence and spread. Cell Microbiol 14:1513-1521. http://dx.doi.org/10.1111/j.1462-5822.2012.01832.x.
5. Hanaki H, Cui L, Ikeda-Dantsuji Y, Nakae T, Honda J, Yanagihara K, Takesue Y, Matsumoto T, Sunakawa K, Kaku M, Tomono K, Fukuchi K, Kusachi S, Mikamo H, Takata T, Otsuka Y, Nagura O, Fujitani S, Aoki Y, Yamaguchi Y, Tateda K, Kadota J, Kohno S, Niki Y. 2014. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011. J Infect Chemother 20:527-534. http://dx.doi .org/10.1016/j.jiac.2014.06.012.
6. Ikeda-Dantsuji Y, Hanaki H, Nakae T, Takesue Y, Tomono K, Honda J, Yanagihara K, Mikamo H, Fukuchi K, Kaku M, Kohno S, Niki Y. 2011. Emergence of linezolid-resistant mutants in a susceptible-cell population of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 55:2466-2468. http://dx.doi.org/10.1128/AAC.01548-10.
7. Mishra NN, Bayer AS, Weidenmaier C, Grau T, Wanner S, Stefani S, Cafiso V, Bertuccio T, Yeaman MR, Nast CC, Yang SJ. 2014. Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons. PLoS One 9:e107426. http://dx.doi.org/10.1371/journal.pone.0107426.
8. Mishra NN, McKinnell J, Yeaman MR, Rubio A, Nast CC, Chen L, Kreiswirth BN, Bayer AS. 2011. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 55:4012-4018. http://dx.doi.org/10.1128/AAC.00223-11.
9. Saravolatz LD, Pawlak J, Johnson L, Bonilla H, Saravolatz LD, II, Fakih MG, Fugelli A, Olsen WM. 2012. In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycinintermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus. Antimicrob Agents Chemother 56:4478-4482. http://dx.doi.org/10.1128/AAC.00194-12.
10. Awasthi D, Kumar K, Ojima I. 2011. Therapeutic potential of FtsZ inhibition: a patent perspective. Expert Opin Ther Pat 21:657-679. http: //dx.doi.org/10.1517/13543776.2011.568483.
11. Lock RL, Harry EJ. 2008. Cell-division inhibitors: new insights for future antibiotics. Nat Rev Drug Discov 7:324-338. http://dx.doi.org/10.1038 /nrd2510.
12. Sass P, Brötz-Oesterhelt H. 2013. Bacterial cell division as a target for new antibiotics. Curr Opin Microbiol 16:522-530. http://dx.doi.org/10.1016/j .mib.2013.07.006.
13. Schaffner-Barbero C, Martin-Fontecha M, Chacón P, Andreu JM. 2012. Targeting the assembly of bacterial cell division protein FtsZ with small molecules. ACS Chem Biol 7:269-277. http://dx.doi.org/10.1021/cb2003626.
14. Vollmer W. 2006. The prokaryotic cytoskeleton: a putative target for inhibitors and antibiotics? Appl Microbiol Biotechnol 73:37-47. http://dx .doi.org/10.1007/s00253-006-0586-0.
15. Adams DW, Errington J. 2009. Bacterial cell division: assembly, maintenance and disassembly of the Z ring. Nat Rev Microbiol 7:642-653. http: //dx.doi.org/10.1038/nrmicro2198.
16. Bi EF, Lutkenhaus J. 1991. FtsZ ring structure associated with division in Escherichia coli. Nature 354:161-164. http://dx.doi.org/10.1038/354161a0.
17. Erickson HP, Anderson DE, Osawa M. 2010. FtsZ in bacterial cytokinesis: cytoskeleton and force generator all in one. Microbiol Mol Biol Rev 74:504-528. http://dx.doi.org/10.1128/MMBR.00021-10.
18. Pinho MG, Errington J. 2003. Dispersed mode of Staphylococcus aureus cell wall synthesis in the absence of the division machinery. Mol Microbiol 50:871-881. http://dx.doi.org/10.1046/j.1365-2958.2003.03719.x.
19. Pinho MG, MKjos Veening J-W. 2013. How to get (a) round: mechanisms controlling growth and division of coccoid bacteria. Nat Rev Microbiol 11:601- 614. http://dx.doi.org/10.1038/nrmicro3088.
20. Tan CM, Therien AG, Lu J, Lee SH, Caron A, Gill CJ, Lebeau-Jacob C, Benton-Perdomo L, Monteiro JM, Pereira PM, Elsen NL, Wu J, Deschamps K, Petcu M, Wong S, Daigneault E, Kramer S, Liang L, Maxwell E, Claveau D, Vaillancourt J, Skorey K, Tam J, Wang H, Meredith TC, Sillaots S, Wang-Jarantow L, Ramtohul Y, Langlois E, Landry F, Reid JC, Parthasarathy G, Sharma S, Baryshnikova A, Lumb KJ, Pinho MG, Soisson SM, Roemer T. 2012. Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Sci Transl Med 4:126ra35. http://dx.doi.org/10.1126/scitranslmed.3003592.
21. Andreu JM, Schaffner-Barbero C, Huecas S, Alonso D, Lopez- Rodriguez ML, Ruiz-Avila LB, Núñez-Rami'rez R, Llorca O, Martín- Galiano AJ. 2010. The antibacterial cell division inhibitor PC190723 is an FtsZ polymer-stabilizing agent that induces filament assembly and condensation. J Biol Chem 285:14239-14246. http://dx.doi.org/10.1074/jbc .M109.094722.
22. Elsen NL, Lu J, Parthasarathy G, Reid JC, Sharma S, Soisson SM, Lumb KJ. 2012. Mechanism of action of the cell-division inhibitor PC190723: modulation of FtsZ assembly cooperativity. J Am Chem Soc 134:12342-12345. http://dx.doi.org/10.1021/ja303564a.
23. Haydon DJ, Stokes NR, Ure R, Galbraith G, Bennett JM, Brown DR, Baker PJ, Barynin VV, Rice DW, Sedelnikova SE, Heal JR, Sheridan JM, Aiwale ST, Chauhan PK, Srivastava A, Taneja A, Collins I, Errington J, Czaplewski LG. 2008. An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 321:1673-1675. http://dx.doi.org/10 .1126/science.1159961.
24. Stokes NR, Sievers J, Barker S, Bennett JM, Brown DR, Collins I, Errington VM, Foulger D, Hall M, Halsey R, Johnson H, Rose V, Thomaides HB, Haydon DJ, Czaplewski LG, Errington J. 2005. Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay. J Biol Chem 280:39709-39715. http://dx.doi.org/10.1074 /jbc.M506741200.
25. Kaul M, Mark L, Zhang Y, Parhi AK, LaVoie EJ, Pilch DS. 2013. Pharmacokinetics and in Vivo antistaphylococcal efficacy of TXY541, a 1-methylpiperidine-4-carboxamide prodrug of PC190723. Biochem Pharmacol 86:1699-1707. http://dx.doi.org/10.1016/j.bcp.2013.10.010.
26. Kaul M, Mark L, Zhang Y, Parhi AK, LaVoie EJ, Pilch DS. 2013. An FtsZ-targeting prodrug with oral antistaphylococcal efficacy in vivo. Antimicrob Agents Chemother 57:5860-5869. http://dx.doi.org/10 .1128/AAC.01016-13.
27. Sorto NA, Olmstead MM, Shaw JT. 2010. Practical synthesis of PC190723, an inhibitor of the bacterial cell division protein FtsZ. J Org Chem 75:7946-7949. http://dx.doi.org/10.1021/jo101720y.
28. th ed, CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
29. Balani SK, Zhu T, Yang TJ, Liu Z, He B, Lee FW. 2002. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metab Dispos 30:1059-1062. http://dx.doi .org/10.1124/dmd.30.10.1059.
30. Kaul M, Parhi AK, Zhang Y, LaVoie EJ, Tuske S, Arnold E, Kerrigan JE, Pilch DS. 2012. A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization. J Med Chem 55:10160-10176. http://dx.doi.org/10.1021/jm3012728.
31. Qi H, Lin C-P, Fu X, Wood LM, Liu AA, Tsai Y-C, Chen Y, Barbieri CM, Pilch DS, Liu LF. 2006. G-quadruplexes induce apoptosis in tumor cells. Cancer Res 66:11808-11816. http://dx.doi.org/10.1158/0008-5472 .CAN-06-1225.
32. Haydon DJ, Bennett JM, Brown D, Collins I, Galbraith G, Lancett P, Macdonald R, Stokes NR, Chauhan PK, Sutariya JK, Nayal N, Srivastava A, Beanland J, Hall R, Henstock V, Noula C, Rockley C, Czaplewski L. 2010. Creating an antibacterial with in vivo efficacy: synthesis and characterization of potent inhibitors of the bacterial cell division protein FtsZ with improved pharmaceutical properties. J Med Chem 53:3927-3936. http://dx.doi.org/10.1021/jm9016366.
33. Adams DW, Wu LJ, Czaplewski LG, Errington J. 2011. Multiple effects of benzamide antibiotics on FtsZ function. Mol Microbiol 80:68-84. http: //dx.doi.org/10.1111/j.1365-2958.2011.07559.x.
34. Kaul M, Zhang Y, Parhi AK, LaVoie EJ, Tuske S, Arnold E, Kerrigan JE, Pilch DS. 2013. Enterococcal and streptococcal resistance to PC190723 and related compounds: molecular insights from a FtsZ mutational analysis. Biochimie 95:1880-1887. http://dx.doi.org/10.1016/j.biochi.2013.06 .010.
35. Gueiros-Filho FJ, Losick R. 2002. A widely conserved bacterial cell division protein that promotes assembly of the tubulin-like protein FtsZ. Genes Dev 16:2544-2556. http://dx.doi.org/10.1101/gad.1014102.